Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 13,437 shares at $649.54 ($8.6M) on 2022-08-16, disclosed to the SEC on 2022-08-17.
Open-market sale of $8.6M REGN by EVP Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $634.25 | 6,487 | $4.1M | 47.8% |
| 2 | $639.85 | 76 | $49K | 0.6% |
| 3 | $640.91 | 148 | $95K | 1.1% |
| 4 | $640.91 | 148 | $95K | 1.1% |
| 5 | $641.47 | 537 | $344K | 4.0% |
| 6 | $641.47 | 537 |
| $344K |
| 4.0% |
| 7 | $642.53 | 329 | $211K | 2.5% |
| 8 | $642.53 | 329 | $211K | 2.5% |
| 9 | $643.37 | 94 | $60K | 0.7% |
| 10 | $643.37 | 94 | $60K | 0.7% |
| 11 | $644.49 | 332 | $214K | 2.5% |
| 12 | $644.49 | 332 | $214K | 2.5% |
| 13 | $645.63 | 119 | $77K | 0.9% |
| 14 | $645.63 | 119 | $77K | 0.9% |
| 15 | $646.44 | 325 | $210K | 2.4% |
| 16 | $646.44 | 325 | $210K | 2.4% |
| 17 | $647.73 | 701 | $454K | 5.3% |
| 18 | $647.73 | 701 | $454K | 5.3% |
| 19 | $648.78 | 766 | $497K | 5.8% |
| 20 | $648.78 | 766 | $497K | 5.8% |
| 21 | $649.54 | 86 | $56K | 0.6% |
| 22 | $649.54 | 86 | $56K | 0.6% |
| Total | $640.09 avg | 13,437 | $8.6M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |